

PharmaJet collaborates with Korea for COVID-19 vaccine delivery

16 September 2020 | News

Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19



PharmaJet[®], the maker of innovative, needle-free injection technology based in the US, has announced that its Stratis[®] Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by Genexine, a leading biotherapeutics company headquartered in South Korea.

The <u>consortium</u> also includes the International Vaccine Institute (IVI), Binex, GenNBio, Korea Advanced Institute for Science and Technology, and Pohang University of Science and Technology.

Genexine's GX-19 vaccine was approved for a Phase I/IIa trial in June by South Korea's MFDS (Ministry of Food and Drug Safety).

The clinical trial of GX-19, the first human study of a COVID-19 preventive vaccine in Korea, is underway and is assessing the safety, tolerability, and immunogenicity in sixty healthy adults aged 19-50 years in Phase 1, and will further expand to enroll an additional 150 people in Phase IIa, to be conducted in Korea this fall.